365 related articles for article (PubMed ID: 32051265)
1. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
2. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
3. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
4. Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
Baraniak I; Kropff B; McLean GR; Pichon S; Piras-Douce F; Milne RSB; Smith C; Mach M; Griffiths PD; Reeves MB
J Infect Dis; 2018 May; 217(12):1907-1917. PubMed ID: 29528415
[TBL] [Abstract][Full Text] [Related]
5. Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.
Baraniak I; Kern F; Holenya P; Griffiths P; Reeves M
J Infect Dis; 2019 Jun; 220(2):228-232. PubMed ID: 30815685
[TBL] [Abstract][Full Text] [Related]
6. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
7. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
8. Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.
Wang HY; Li L; Nelson CS; Barfield R; Valencia S; Chan C; Muramatsu H; Lin PJC; Pardi N; An Z; Weissman D; Permar SR
NPJ Vaccines; 2024 Feb; 9(1):38. PubMed ID: 38378950
[TBL] [Abstract][Full Text] [Related]
9. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
10. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
[TBL] [Abstract][Full Text] [Related]
11. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
12. Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity.
Perotti M; Marcandalli J; Demurtas D; Sallusto F; Perez L
PLoS Pathog; 2020 Dec; 16(12):e1009169. PubMed ID: 33370407
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
Webster H; Valencia S; Kumar A; Chan C; Dennis M; Roark H; Woods A; John S; Carfi A; Permar SR
Vaccine; 2021 Sep; 39(38):5358-5367. PubMed ID: 34393017
[TBL] [Abstract][Full Text] [Related]
14. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
15. Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
Yamaguchi K; Shimizu H; Takahashi K; Nagatomo T; Nishimura T; Matsumoto M; Koshizuka T; Mori H; Inoue N; Torikai M
Vaccine; 2023 Jul; 41(31):4497-4507. PubMed ID: 37321896
[TBL] [Abstract][Full Text] [Related]
16. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
17. Dominant Antiviral CD8
Pardieck IN; van Duikeren S; Veerkamp DMB; Brasem DJ; Redeker A; van Bergen J; Han W; Ossendorp F; Zondag G; Arens R
Front Immunol; 2022; 13():680559. PubMed ID: 35154089
[TBL] [Abstract][Full Text] [Related]
18. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.
Wen Y; Monroe J; Linton C; Archer J; Beard CW; Barnett SW; Palladino G; Mason PW; Carfi A; Lilja AE
Vaccine; 2014 Jun; 32(30):3796-804. PubMed ID: 24837507
[TBL] [Abstract][Full Text] [Related]
19. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
Marshall BC; Adler SP
Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
[TBL] [Abstract][Full Text] [Related]
20. Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection.
Goodwin ML; Webster HS; Wang HY; Jenks JA; Nelson CS; Tu JJ; Mangold JF; Valencia S; Pollara J; Edwards W; McLellan JS; Wrapp D; Fu TM; Zhang N; Freed DC; Wang D; An Z; Permar SR
Virology; 2020 Sep; 548():182-191. PubMed ID: 32838941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
